Creative Biolabs Launches Advanced Neuroscience Platforms to Address Growing Neurodegenerative Disease Research Needs

The global neuroscience research landscape is undergoing significant transformation as Creative Biolabs unveils advanced platforms designed to accelerate brain research, particularly in response to the escalating prevalence of neurodegenerative diseases. With the World Health Organization reporting more than 55 million people currently living with dementia worldwide and Alzheimer's disease accounting for up to 70% of dementia cases, the demand for sophisticated research tools has never been greater.

Creative Biolabs has developed a comprehensive Schwann Cell Assay platform that addresses critical needs in peripheral nervous system research. This innovative platform enables researchers to isolate Schwann cells from three different species—human, mouse, and rat—providing essential tools for studying axonal regeneration and myelination processes. The platform's co-culture system with neurons allows scientists to assess vital functional measures including neurotrophic factor secretion and myelination potential, both of which are fundamental to advancing regenerative medicine approaches for neurological disorders.

In parallel, the company has launched its microglia phagocytosis assay service, which represents a significant advancement in central nervous system research. This service utilizes live-cell imaging and fluorescently labelled bioparticles to enable researchers to visualize microglial phagocytic function in real time. Given that microglia serve as the brain's resident immune cells and play crucial roles in maintaining neural homeostasis, responding to neuroinflammation, and eliminating pathological protein aggregates, this technology provides unprecedented insights into mechanisms underlying neurodegenerative diseases.

The company has also developed comprehensive preclinical and research assessment services for Alzheimer's disease models, featuring both 2D and 3D platforms that accurately represent key disease aspects including amyloid deposition, tauopathy, and neuroinflammation. These models can replicate both familial and sporadic forms of Alzheimer's disease using patient-derived induced pluripotent stem cells (iPSCs), creating more physiologically relevant contexts for drug screening and mechanistic studies. Researchers can access these advanced tools through https://neuros.creative-biolabs.com/ to enhance their investigations into neurodegenerative disease mechanisms.

The timing of these platform launches coincides with increasing global attention on neurodegenerative disease research, particularly as aging populations worldwide contribute to rising incidence rates of conditions like Alzheimer's disease. These technological advancements enable more precise modeling of disease pathology and more efficient screening of potential therapeutic compounds, potentially accelerating the development of effective treatments for millions affected by neurological disorders.